Name: Recombinant Human Anti-MSLN x Human Anti-4-1BB Bispecific Antibody (IgG(H)-scFv)
SKU: KN-0825-N12
Rating: 5 (1 reviews)

Recombinant Human Anti-MSLN x Human Anti-4-1BB Bispecific Antibody (IgG(H)-scFv) is designed to be expressed as a LC and an extended HC with scFv moiety linked to the C terminus. The anti-4-1BB scFvs are fused to the C terminus of the anti-MSLN IgG-Fc chain. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can activate 4-1BB signaling, leading to T cell activation against CLDN18.2-overexpressing tumors. It is designed for the research of Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

MSLN & 4-1BB

Type

IgG-scFv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Solid tumors

Host Animal 1

Human

Host Animal 2

Human

Targets

Target 1

MSLN

Gene ID

10232

UniProt ID

Q13421

Alternative Names

Pre-pro-megakaryocyte-potentiating factor; Pre-pro-MPF; CAK1 antigen; Surface antigen SMR; Mesothelin isoform 1-4; MPF; SMRP; MSLN; mesothelin; CAK1 antigen; Megakaryocyte-potentiating factor; Mesothelin, cleaved form

Target 2

4-1BB

Gene ID

3604

UniProt ID

Q07011

Alternative Names

CD137; Cluster of Differentiation 137; 4-1BB; 4-1BB Receptor; ILA; Induced by Lymphocyte Activation; T-cell Antigen 4-1BB Homolog; CDw137; IMD109; 4-1BB ligand receptor; Tumor necrosis factor receptor superfamily member 9; T-cell antigen ILA

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-MSLN x Human Anti-4-1BB Bispecific Antibody (IgG(H)-scFv) (KN-0825-N12). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-MSLN x Human Anti-4-1BB Bispecific Antibody (IgG(H)-scFv) (CAT#: KN-0825-N12)

Specifications

Targets

Customer Reviews and Q&As